|
NCCN Guidelines® Insights - Survivorship, Version 2.2025 |
1.00 |
06/10/2025 - 12:00am to 06/10/2026 - 12:00am |
|
Updates in Metastatic Colorectal Cancer |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Treatment Updates for Small Cell Lung Cancer |
0.50 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Treatment for Pleural and Peritoneal Mesothelioma |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Management of Immune Checkpoint Inhibitor-Related Toxicities |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Newer Approaches to Treatment of Bladder Cancer |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Smoking Cessation for Patients with Cancer: State of the Evidence |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Updates to Management of Multiple Myeloma |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Updates to Systemic Therapy for Differentiated Thyroid Cancer |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Advances in Head and Neck Cancers: Nasopharyngeal and Oral Cancers |
1.00 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
|
Updates to the Management of Cervical Cancer |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Facebook
X
LinkedIn
Forward